Intellikine Inc.
By
Deborah Erickson / Email the Author / START-UP October 2009, Vol. 14, No. 9
Grouped Start-Ups / Word Count: 1600 / Article # 2009900205
Executive Summary
Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.
$85.00
Buy Now
For $85.00, purchase this 1600-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.